Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia

References

• AlphsLBossieCASliwaJKFuDJMaYWHulihanJPaliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychoticsNeuropsychiatr Disease Treat20139341350
   PubMed Web of Science ®Google Scholar
• KaneJMGarcia-RiberaCClinical guideline recommendations for antipsychotic long-acting injectionsBr J Psychiatry Suppl200952S63S6719880920
   PubMedGoogle Scholar
• MorkenGWidenJHGraweRWNon-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophreniaBMC Psychiatry200883218447935
   PubMed Web of Science ®Google Scholar
• NichollDAkhrasKSDielsJSchadrackJBurden of schizophrenia in recently diagnosed patients: healthcare utilisation and cost perspectiveCurr Med Res Opin20102694395520163295
   PubMed Web of Science ®Google Scholar
• SchreinerAHargarterLHitschfieldKClinical effectiveness and resource utilization of paliperidone ER for schizophrenia: pharmacoepidemiologic international longitudinal antipsychotic registry (PILAR)Curr Med Res Opin2014301279128924597755
   PubMed Web of Science ®Google Scholar
• LacroJPDunnLBDolderCRLeckbandSGJesteDVPrevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literatureJ Clin Psychiatry20026389290912416599
   PubMed Web of Science ®Google Scholar
• OlivaresJMPinalBCinosCComparison of long-acting antipsychotic injection and oral antipsychotics in schizophreniaNeuropsychiatry20111275289
   Google Scholar
• OlivaresJMThirunavukarasuMKulkarniJZhangHYZhangMZhangFPsychiatrists’ awareness of partial and nonadherence to antipsychotic medication in schizophrenia: results from an Asia–Pacific surveyNeuropsychiatr Disease Treat201391163
   Web of Science ®Google Scholar
• AltamuraACAgugliaEBassiMRethinking the role of long-acting atypical antipsychotics in the community settingInt Clin Psychopharmacol20122733634922859065
   PubMed Web of Science ®Google Scholar
• ValensteinMBlowFCCopelandLAPoor antipsychotic adherence among patients with schizophrenia: medication and patient factorsSchizophrenia Bull200430255264
   PubMed Web of Science ®Google Scholar
• WeidenPJKozmaCGroggALocklearJPartial compliance and risk of rehospitalization among California medicaid patients with schizophreniaPsychiatr Serv20045588689115292538
   PubMed Web of Science ®Google Scholar
• RobinsonDGMedication adherence and relapse in recent-onset psychosisAm J Psychiatry201116824024221368304
   PubMed Web of Science ®Google Scholar
• SubotnikKLNuechterleinKHVenturaJRisperidone nonadherence and return of positive symptoms in the early course of schizophreniaAm J Psychiatry201116828629221205805
   PubMed Web of Science ®Google Scholar
• BottlenderRSatoTJagerMThe impact of the duration of untreated psychosis prior to first psychiatric admission on the 15-year outcome in schizophreniaSchizophrenia Res2003623744
   PubMed Web of Science ®Google Scholar
• HarriganSMMcGorryPDKrstevHDoes treatment delay in first-episode psychosis really matter?Psychol Med2003339711012537041
   PubMed Web of Science ®Google Scholar
• EmsleyROosthuizenPKoenLNiehausDJMedoriRRabinowitzJRemission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injectionInt Clin Psychopharmacol20082332533118854720
   PubMed Web of Science ®Google Scholar
• SliwaJKBossieCAFuDJTurkozIAlphsLLong-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophreniaNeuropsychiatr Disease Treat20128375385
   PubMed Web of Science ®Google Scholar
• RobinsonDGWoernerMGDelmanHMKaneJMPharmacological treatments for first-episode schizophreniaSchizophrenia Bull200531705722
   PubMed Web of Science ®Google Scholar
• LeuchtCHeresSKaneJMKisslingWDavisJMLeuchtSOral versus depot antipsychotic drugs for schizophrenia – a critical systematic review and meta-analysis of randomised long-term trialsSchizophrenia Res20111278392
   PubMed Web of Science ®Google Scholar
• SchreinerAAadamsooKAltamuraACA randomized, active-controlled rater-blinded 2-year study of paliperidone palmitate versus investigators’ choice of oral antipsychotic monotherapy in patients with schizophrenia (PROSIPAL)22nd European Congress of Psychiatry (European Psychiatric Association)Munich, Germany2014188189
   Google Scholar
• AlphsLMahalchickLCMaoLStarrLPaliperidone research in demonstrating effectiveness (pride): functioning in subjects with schizophrenia and a history of incarceration167th Annual Meeting Of American Psychiatric AssociationNew York, USA2014
   Google Scholar
• AgidOFoussiasGRemingtonGLong-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse preventionExpert Opin Pharmacother20101123011720586707
   PubMed Web of Science ®Google Scholar
• KaneJMReducing non-adherence: new formulations of antipsychotic medicationsPsychiatric Times200625
   Google Scholar
• NasrallahHAThe case for long-acting antipsychotic agents in the post-CATIE eraActa Psychiatr Scand200711526026717355516
   PubMed Web of Science ®Google Scholar
• SamtaniMNSheehanJJFuDJRemmerieBSliwaJKAlphsLManagement of antipsychotic treatment discontinuation and interruptions using model-based simulationsClin Pharmacol20124254022888277
   PubMedGoogle Scholar
• SchoolerNRRelapse and rehospitalization: comparing oral and depot antipsychoticsJ Clin Psychiatry200364Suppl 16141714680414
   PubMed Web of Science ®Google Scholar
• ZhuBAscher-SvanumHShiLFariesDMontgomeryWMarderSRTime to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophreniaPsychiatr Serv20085931531718308914
   PubMed Web of Science ®Google Scholar
• AltamuraACSassellaFSantiniAMontresorCFumagalliSMundoEIntramuscular preparations of antipsychotics: uses and relevance in clinical practiceDrugs20036349351212600227
   PubMed Web of Science ®Google Scholar
• NewtonRHustigHLakshmanaRPractical guidelines on the use of paliperidone palmitate in schizophreniaCurr Med Res Opin20122855956722321007
   PubMed Web of Science ®Google Scholar
• AlphsLBossieCASliwaJKMaYWTurnerNOnset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trialAnn Gen Psychiatry2011101221481243
   PubMed Web of Science ®Google Scholar
• AttardAOlofinjanaOCorneliusVCurtisVTaylorDPaliperidone palmitate long-acting injection–prospective year-long follow-up of use in clinical practiceActa Psychiatr Scandinavica20141304651
   PubMed Web of Science ®Google Scholar
• BossieCAFuDJSliwaJKMaYWAlphsLTolerability of initiation doses of once-monthly paliperidone palmitate in patients with recently diagnosed schizophrenia in an acute treatment trialTher Adv Psychopharmacol2011111112423983935
   PubMedGoogle Scholar
• CoppolaDLiuYGopalSA one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophreniaBMC Psychiatry2012122622455454
   PubMed Web of Science ®Google Scholar
• FuDJBossieCASliwaJKMaYWAlphsLPaliperidone palmitate versus oral risperidone and risperidone long-acting injection in patients with recently diagnosed schizophrenia: a tolerability and efficacy comparisonInt Clin Psychopharmacol201429455524113628
   PubMed Web of Science ®Google Scholar
• GopalSVijapurkarULimPMorozovaMEerdekensMHoughDA 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophreniaJ Psychopharmacol20112568569720615933
   PubMed Web of Science ®Google Scholar
• HoughDGopalSVijapurkarULimPMorozovaMEerdekensMPaliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled studySchizophrenia Res2010116107117
   PubMed Web of Science ®Google Scholar
• KramerMLitmanRHoughDPaliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety studyInt J Neuropsychopharmacol20101363564719941696
   PubMed Web of Science ®Google Scholar
• PandinaGLaneRGopalSA double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophreniaProg Neuropsychopharmacol Biol Psychiatry20113521822621092748
   PubMed Web of Science ®Google Scholar
• PandinaGJLindenmayerJPLullJA randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophreniaJ Clin Psychopharmacol20103023524420473057
   PubMed Web of Science ®Google Scholar
• TaylorDOlofinjanaOLong-acting paliperidone palmitate–interim results of an observational study of its effect on hospitalizationInt Clin Psychopharmacol20142922923424419004
   PubMed Web of Science ®Google Scholar
• LiHRuiQNingXXuHGuNA comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophreniaProg Neuropsychopharmacol Biol Psychiatry2011351002100821315787
   PubMed Web of Science ®Google Scholar
• TakahashiNTakahashiMSaitoTRandomized, placebo-controlled, double-blind study assessing the efficacy and safety of paliperidone palmitate in Asian patients with schizophreniaNeuropsychiatr Disease Treat2013818891898
   PubMed Web of Science ®Google Scholar
• AndreasenNCCarpenterWTJrKaneJMLasserRAMarderSRWeinbergerDRRemission in schizophrenia: proposed criteria and rationale for consensusAm J Psychiatry200516244144915741458
   PubMed Web of Science ®Google Scholar
• FleischhackerWWolfgangRDMcQuadeRNMarcusDARenéSWilliamHCA double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophreniaBiol Psychiatry20096551051718986646
   PubMed Web of Science ®Google Scholar
• GopalSHoughDWXuHEfficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response studyInt Clin Psychopharmacol20102524725620389255
   PubMed Web of Science ®Google Scholar
• NasrallahHAGopalSGassmann-MayerCA controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophreniaNeuropsychopharmacology2010352072208220555312
   PubMed Web of Science ®Google Scholar
• WeidenPJSchoolerNRWeedonJCElmouchtariASunakawaAGoldfingerSMA randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcomeJ Clin Psychiatry2009701397140619906343
   PubMed Web of Science ®Google Scholar
• OlivaresJMRodriguez-MoralesADielsJLong-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic schizophrenia treatment adherence registry (e-STAR)Eur Psychiatry20092428729619195847
   PubMed Web of Science ®Google Scholar
• ChuePLlorcaP-MDuehesneILealARosillonDMehnertAHospitalization rates in patients during long-term treatment with long-acting risperidone injectionJ Appl Res200552266274
   Google Scholar
• FullerMShermockKRussoPHospitalisation and resource utilisation in patients with schizophrenia following initiation of risperidone long-acting therapy in the veterans affairs healthcare systemJ Med Econ20091231732419817665
   PubMedGoogle Scholar
• KoczerginskiDArshoffLHospital resource use by patients with schizophrenia: reduction after conversion from oral treatment to risperidone long-acting injectionHealthc Q201114828721301245
   PubMedGoogle Scholar
• KozmaCMSlatonTDiraniRFastenauJGopalSHoughDChanges in schizophrenia-related hospitalization and ER use among patients receiving paliperidone palmitate: results from a clinical trial with a 52-week open-label extension (OLE)Curr Med Res Opin2011271603161121696265
   PubMed Web of Science ®Google Scholar
• LambertTOlivaresJMPeuskensJEffectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and BelgiumAnn Gen Psychiatry2011101021463526
   PubMed Web of Science ®Google Scholar
• SuKPChangHCTsaiSJYenFCTangCHRelapse and long-acting injectable risperidone: a 1-year mirror image study with a national claims database in TaiwanValue Health200912Suppl 3S118S12120586973
   PubMed Web of Science ®Google Scholar
• TaylorMCurrieALloydKPriceMPeperellKImpact of risperidone long acting injection on resource utilization in psychiatric secondary careJ Psychopharmacol20082212813118308820
   PubMed Web of Science ®Google Scholar
• WillisMSvenssonMLothgrenMErikssonBBerntssonAPerssonUThe impact on schizophrenia-related hospital utilization and costs of switching to long-acting risperidone injections in SwedenEur J Health Econ20101158559420084535
   PubMed Web of Science ®Google Scholar
• KishimotoTRobenzadehALeuchtCLong-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trialsSchizophrenia Bull201440192213
   PubMed Web of Science ®Google Scholar
• KishimotoTNittaMBorensteinMKaneJMCorrellCULong-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studiesJ Clin Psychiatry20137495796524229745
   PubMed Web of Science ®Google Scholar
• GildayENasrallahHAClinical pharmacology of paliperidone palmitate a parenteral long-acting formulation for the treatment of schizophreniaRev Recent Clin Trials201272922023179
   PubMedGoogle Scholar
• JannoSHoliMTuiskuKWahlbeckKPrevalence of neuroleptic-induced movement disorders in chronic schizophrenia inpatientsAm J Psychiatry200416116016314702266
   PubMed Web of Science ®Google Scholar
• KasperSFirst-episode schizophrenia: the importance of early intervention and subjective tolerabilityJ Clin Psychiatry199960Suppl 235910625193
   PubMed Web of Science ®Google Scholar
• KellyDLConleyRRCarpenterWTFirst-episode schizophrenia: a focus on pharmacological treatment and safety considerationsDrugs2005651113113815907146
   PubMed Web of Science ®Google Scholar
• SerrettiADe RonchiDLorenziCBerardiDNew antipsychotics and schizophrenia: a review on efficacy and side effectsCurr Med Chem20041134335814965236
   PubMed Web of Science ®Google Scholar